Cargando…
Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669135/ https://www.ncbi.nlm.nih.gov/pubmed/23741510 http://dx.doi.org/10.1371/journal.pone.0065719 |
_version_ | 1782271705431932928 |
---|---|
author | Lu, Mong-Liang Lin, Chia-Hui Chen, Yi-Chuan Yang, Huai-Chih Wu, Tzu-Hua |
author_facet | Lu, Mong-Liang Lin, Chia-Hui Chen, Yi-Chuan Yang, Huai-Chih Wu, Tzu-Hua |
author_sort | Lu, Mong-Liang |
collection | PubMed |
description | BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, but this remains unclear. Our aim was to explore the correlation between the concentrations of OLZ or DMO with various metabolic parameters in schizophrenic patients. METHODS: The chromatographic analysis was carried out with a solvent delivery system coupled to a Coulochem III coulometric detector to determine OLZ and DMO simultaneously in OLZ-treated patients. The correlation between the concentration of OLZ or DMO and the metabolic parameters was analyzed by the Spearman rank order correlation method (r (s)). PRINCIPAL FINDINGS: The established analytical method met proper standards for accuracy and reliability and the lower limitation of quantification for each injection of DMO or OLZ was 0.02 ng. The method was successfully used for the analysis of samples from nonsmoking patients (n = 48) treated with OLZ in the dosage range of 5–20 mg per day. There was no correlation between OLZ concentrations and tested metabolic parameters. DMO concentrations were negatively correlated with glucose (r (s) = –0.45) and DMO concentrations normalized by doses were also negatively correlated with insulin levels (r (s) = –0.39); however, there was a marginally positive correlation between DMO and homocysteine levels (r (s) = +0.38). CONCLUSIONS: The observed negative correlations between levels of DMO and glucose or insulin suggest a metabolic normalization role for DMO regardless of its positive correlation with a known cardiovascular risk factor, homocysteine. Additional studies of the mechanisms underlying DMO’s metabolic effects are warranted. |
format | Online Article Text |
id | pubmed-3669135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36691352013-06-05 Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters Lu, Mong-Liang Lin, Chia-Hui Chen, Yi-Chuan Yang, Huai-Chih Wu, Tzu-Hua PLoS One Research Article BACKGROUND: Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, but this remains unclear. Our aim was to explore the correlation between the concentrations of OLZ or DMO with various metabolic parameters in schizophrenic patients. METHODS: The chromatographic analysis was carried out with a solvent delivery system coupled to a Coulochem III coulometric detector to determine OLZ and DMO simultaneously in OLZ-treated patients. The correlation between the concentration of OLZ or DMO and the metabolic parameters was analyzed by the Spearman rank order correlation method (r (s)). PRINCIPAL FINDINGS: The established analytical method met proper standards for accuracy and reliability and the lower limitation of quantification for each injection of DMO or OLZ was 0.02 ng. The method was successfully used for the analysis of samples from nonsmoking patients (n = 48) treated with OLZ in the dosage range of 5–20 mg per day. There was no correlation between OLZ concentrations and tested metabolic parameters. DMO concentrations were negatively correlated with glucose (r (s) = –0.45) and DMO concentrations normalized by doses were also negatively correlated with insulin levels (r (s) = –0.39); however, there was a marginally positive correlation between DMO and homocysteine levels (r (s) = +0.38). CONCLUSIONS: The observed negative correlations between levels of DMO and glucose or insulin suggest a metabolic normalization role for DMO regardless of its positive correlation with a known cardiovascular risk factor, homocysteine. Additional studies of the mechanisms underlying DMO’s metabolic effects are warranted. Public Library of Science 2013-05-31 /pmc/articles/PMC3669135/ /pubmed/23741510 http://dx.doi.org/10.1371/journal.pone.0065719 Text en © 2013 Lu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Lu, Mong-Liang Lin, Chia-Hui Chen, Yi-Chuan Yang, Huai-Chih Wu, Tzu-Hua Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title | Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title_full | Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title_fullStr | Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title_full_unstemmed | Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title_short | Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters |
title_sort | determination of olanzapine and n-desmethyl-olanzapine in plasma using a reversed-phase hplc coupled with coulochemical detection: correlation of olanzapine or n-desmethyl-olanzapine concentration with metabolic parameters |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669135/ https://www.ncbi.nlm.nih.gov/pubmed/23741510 http://dx.doi.org/10.1371/journal.pone.0065719 |
work_keys_str_mv | AT lumongliang determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters AT linchiahui determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters AT chenyichuan determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters AT yanghuaichih determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters AT wutzuhua determinationofolanzapineandndesmethylolanzapineinplasmausingareversedphasehplccoupledwithcoulochemicaldetectioncorrelationofolanzapineorndesmethylolanzapineconcentrationwithmetabolicparameters |